Clinical Trials
22 trialsNCT04762602 2026-03-27
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
Phase 1 Terminated
NCT05346484 2026-03-06
MAST
Imugene Limited
Phase 1 Terminated
NCT05194072 2026-01-09
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT06420349 2025-12-22
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Terminated
NCT03144661 2025-10-21
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Phase 1 Terminated
NCT06336148 2025-10-15
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Phase 1 Terminated
NCT02784795 2025-08-21
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT05432193 2025-06-25
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
Phase 1 Terminated
NCT05242822 2025-05-07
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Kinnate Biopharma
Phase 1 Terminated
NCT05501912 2024-11-29
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
ABM Therapeutics Shanghai Company Limited
Phase 1 Terminated
NCT02714374 2024-08-06
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
University of California, San Diego
Phase 1 Terminated
NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
NCT04088188 2024-05-06
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Academic and Community Cancer Research United
Phase 1 Terminated
NCT04304781 2022-11-22
Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
University of Michigan
Phase 1 Terminated
NCT01525069 2022-08-10
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Washington University School of Medicine
Phase 1 Terminated
NCT02908451 2021-07-13
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
AbGenomics B.V Taiwan Branch
Phase 1 Terminated
NCT02757391 2020-10-30
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02012231 2020-10-19
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Fore Biotherapeutics
Phase 1 Terminated
NCT03267940 2020-02-07
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Halozyme Therapeutics
Phase 1 Terminated
NCT00630890 2015-09-11
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
University of California, San Francisco
Phase 1 Terminated
NCT01434459 2015-05-04
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Emory University
Phase 1 Terminated
NCT00426829 2012-08-01
Proton Therapy and Bevacizumab for Primary Liver Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated